conivaptan hydrochloride	Moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	Moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	Moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	Moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	Conivaptan	16	14	true	negative	The pharmacokinetics of conivaptan following intravenous infusion (40 mg/day to 80 mg/day) and oral administration are non-linear, and inhibition by conivaptan of its own metabolism seems to be the major factor for the non-linearity.  The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
conivaptan hydrochloride	Conivaptan	16	15	true	negative	The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
conivaptan hydrochloride	Conivaptan	16	17	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  Mean Cmax for conivaptan was 619 ng/mL and occurred at the end of the loading dose.  		C106389	302285
conivaptan hydrochloride	Conivaptan	16	16	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
conivaptan hydrochloride	Conivaptan	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		C106389	302285
conivaptan hydrochloride	Conivaptan	20	19	false	none	The mean terminal elimination half-life after conivaptan infusion was 5.0 hours, and the mean clearance was 253.3 mL/min.  In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
conivaptan hydrochloride	Conivaptan	20	21	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  The median-plasma conivaptan concentrations are shown in Figure 1.  		C106389	302285
conivaptan hydrochloride	Conivaptan	20	20	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
conivaptan hydrochloride	Conivaptan	5	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  		C106389	302285
conivaptan hydrochloride	Conivaptan	5	6	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
conivaptan hydrochloride	Conivaptan	5	7	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	Conivaptan	6	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
conivaptan hydrochloride	Conivaptan	6	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
conivaptan hydrochloride	Conivaptan	6	7	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	Conivaptan	7	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	Conivaptan	7	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	Conivaptan	7	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	Conivaptan	28	27	false	none	The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
conivaptan hydrochloride	Conivaptan	28	26	false	none	The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
conivaptan hydrochloride	Conivaptan	28	29	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  		C106389	302285
conivaptan hydrochloride	Conivaptan	28	28	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
conivaptan hydrochloride	Conivaptan	28	30	false	none	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  		C106389	302285
conivaptan hydrochloride	vasopressin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
conivaptan hydrochloride	vasopressin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
conivaptan hydrochloride	conivaptan	16	14	true	negative	The pharmacokinetics of conivaptan following intravenous infusion (40 mg/day to 80 mg/day) and oral administration are non-linear, and inhibition by conivaptan of its own metabolism seems to be the major factor for the non-linearity.  The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
conivaptan hydrochloride	conivaptan	16	15	true	negative	The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
conivaptan hydrochloride	conivaptan	16	17	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  Mean Cmax for conivaptan was 619 ng/mL and occurred at the end of the loading dose.  		C106389	302285
conivaptan hydrochloride	conivaptan	16	16	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
conivaptan hydrochloride	conivaptan	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		C106389	302285
conivaptan hydrochloride	conivaptan	20	19	false	none	The mean terminal elimination half-life after conivaptan infusion was 5.0 hours, and the mean clearance was 253.3 mL/min.  In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
conivaptan hydrochloride	conivaptan	20	21	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  The median-plasma conivaptan concentrations are shown in Figure 1.  		C106389	302285
conivaptan hydrochloride	conivaptan	20	20	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
conivaptan hydrochloride	conivaptan	5	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  		C106389	302285
conivaptan hydrochloride	conivaptan	5	6	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
conivaptan hydrochloride	conivaptan	5	7	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	conivaptan	6	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
conivaptan hydrochloride	conivaptan	6	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
conivaptan hydrochloride	conivaptan	6	7	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	conivaptan	7	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	conivaptan	7	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	conivaptan	7	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
conivaptan hydrochloride	conivaptan	28	27	false	none	The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
conivaptan hydrochloride	conivaptan	28	26	false	none	The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
conivaptan hydrochloride	conivaptan	28	29	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  		C106389	302285
conivaptan hydrochloride	conivaptan	28	28	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
conivaptan hydrochloride	conivaptan	28	30	false	none	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  		C106389	302285
conivaptan hydrochloride	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
conivaptan hydrochloride	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
conivaptan hydrochloride	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
conivaptan hydrochloride	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
conivaptan hydrochloride	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
conivaptan hydrochloride	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
conivaptan hydrochloride	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
Moxifloxacin	Conivaptan hydrochloride	8	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	C106389
Moxifloxacin	Conivaptan hydrochloride	8	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	C106389
Moxifloxacin	Conivaptan hydrochloride	8	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	C106389
Moxifloxacin	Conivaptan hydrochloride	8	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	C106389
Moxifloxacin	Conivaptan	8	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	Conivaptan	8	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	Conivaptan	8	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	Conivaptan	8	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	Conivaptan	10	12	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		139462	302285	139462	302285
Moxifloxacin	Conivaptan	10	12	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		139462	302285	139462	302285
Moxifloxacin	conivaptan	8	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	conivaptan	8	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	conivaptan	8	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	conivaptan	8	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	302285	139462	302285
Moxifloxacin	conivaptan	10	12	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		139462	302285	139462	302285
Moxifloxacin	conivaptan	10	12	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		139462	302285	139462	302285
Moxifloxacin	VAPRISOL	8	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	0	139462	616622
Moxifloxacin	VAPRISOL	8	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	0	139462	616622
Moxifloxacin	VAPRISOL	10	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  Digital ECGs were obtained at baseline and on Days 1 and 4.  Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  		139462	0	139462	616622
Moxifloxacin	VAPRISOL	10	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  Digital ECGs were obtained at baseline and on Days 1 and 4.  Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  		139462	0	139462	616622
Moxifloxacin	VAPRISOL	10	11	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  		139462	0	139462	616622
Moxifloxacin	VAPRISOL	10	11	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  		139462	0	139462	616622
Conivaptan hydrochloride	Conivaptan	16	14	true	negative	The pharmacokinetics of conivaptan following intravenous infusion (40 mg/day to 80 mg/day) and oral administration are non-linear, and inhibition by conivaptan of its own metabolism seems to be the major factor for the non-linearity.  The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	16	15	true	negative	The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	16	17	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  Mean Cmax for conivaptan was 619 ng/mL and occurred at the end of the loading dose.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	16	16	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	20	19	false	none	The mean terminal elimination half-life after conivaptan infusion was 5.0 hours, and the mean clearance was 253.3 mL/min.  In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	20	21	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  The median-plasma conivaptan concentrations are shown in Figure 1.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	20	20	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	5	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	5	6	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	5	7	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	6	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	6	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	6	7	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	7	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	7	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	7	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	28	27	false	none	The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	28	26	false	none	The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	28	29	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	28	28	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
Conivaptan hydrochloride	Conivaptan	28	30	false	none	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  		C106389	302285
Conivaptan hydrochloride	vasopressin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
Conivaptan hydrochloride	vasopressin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
Conivaptan hydrochloride	conivaptan	16	14	true	negative	The pharmacokinetics of conivaptan following intravenous infusion (40 mg/day to 80 mg/day) and oral administration are non-linear, and inhibition by conivaptan of its own metabolism seems to be the major factor for the non-linearity.  The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
Conivaptan hydrochloride	conivaptan	16	15	true	negative	The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
Conivaptan hydrochloride	conivaptan	16	17	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  Mean Cmax for conivaptan was 619 ng/mL and occurred at the end of the loading dose.  		C106389	302285
Conivaptan hydrochloride	conivaptan	16	16	false	none	The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.  		C106389	302285
Conivaptan hydrochloride	conivaptan	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		C106389	302285
Conivaptan hydrochloride	conivaptan	20	19	false	none	The mean terminal elimination half-life after conivaptan infusion was 5.0 hours, and the mean clearance was 253.3 mL/min.  In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
Conivaptan hydrochloride	conivaptan	20	21	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  The median-plasma conivaptan concentrations are shown in Figure 1.  		C106389	302285
Conivaptan hydrochloride	conivaptan	20	20	false	none	In an open-label safety and efficacy study, the pharmacokinetics of conivaptan were characterized in hypervolemic or euvolemic hyponatremia patients (ages 20 - 92 years) receiving conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 20 or 40 mg/day for 4 days.  		C106389	302285
Conivaptan hydrochloride	conivaptan	5	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  		C106389	302285
Conivaptan hydrochloride	conivaptan	5	6	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
Conivaptan hydrochloride	conivaptan	5	7	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	conivaptan	6	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
Conivaptan hydrochloride	conivaptan	6	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  		C106389	302285
Conivaptan hydrochloride	conivaptan	6	7	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	conivaptan	7	5	false	none	The predominant pharmacodynamic effect of conivaptan hydrochloride in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water.  12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	conivaptan	7	6	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	conivaptan	7	7	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  		C106389	302285
Conivaptan hydrochloride	conivaptan	28	27	false	none	The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
Conivaptan hydrochloride	conivaptan	28	26	false	none	The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  The combined exposure of the metabolites following intravenous administration of conivaptan is approximately 7% that of conivaptan and hence, their contribution to the clinical effect of conivaptan is minimal.  After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
Conivaptan hydrochloride	conivaptan	28	29	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  		C106389	302285
Conivaptan hydrochloride	conivaptan	28	28	true	positive	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  		C106389	302285
Conivaptan hydrochloride	conivaptan	28	30	false	none	After intravenous (10 mg) or oral (20 mg) administration of conivaptan hydrochloride in a mass balance study, approximately 83% of the dose was excreted in feces as total radioactivity and 12% in urine over several days of collection.  Over the first 24 hours after dosing, approximately 1% of the intravenous dose was excreted in urine as intact conivaptan.  Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  		C106389	302285
Conivaptan hydrochloride	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
Conivaptan hydrochloride	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	C106389	none
Conivaptan hydrochloride	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
Conivaptan hydrochloride	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
Conivaptan hydrochloride	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
Conivaptan hydrochloride	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	C106389	139462
Conivaptan hydrochloride	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
Conivaptan hydrochloride	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
Conivaptan hydrochloride	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
Conivaptan hydrochloride	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	C106389	616622
Conivaptan	vasopressin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	302285	none
Conivaptan	vasopressin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	302285	none
Conivaptan	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	302285	none
Conivaptan	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	302285	none
Conivaptan	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
Conivaptan	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
Conivaptan	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
Conivaptan	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
Conivaptan	moxifloxacin	12	10	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	139462	302285	139462
Conivaptan	moxifloxacin	12	10	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	139462	302285	139462
Conivaptan	VAPRISOL	34	35	false	none	However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	34	35	false	none	However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	34	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  		302285	0	302285	616622
Conivaptan	VAPRISOL	34	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  		302285	0	302285	616622
Conivaptan	VAPRISOL	35	35	false	none	In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	35	35	false	none	In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	32	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	32	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	33	35	false	none	Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	33	35	false	none	Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	33	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  		302285	0	302285	616622
Conivaptan	VAPRISOL	33	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  		302285	0	302285	616622
Conivaptan	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
Conivaptan	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
Conivaptan	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
Conivaptan	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
Conivaptan	VAPRISOL	12	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	0	302285	616622
Conivaptan	VAPRISOL	12	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	0	302285	616622
Conivaptan	VAPRISOL	13	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  12.3 Pharmacokinetics    The pharmacokinetics of conivaptan have been characterized in healthy subjects, special populations and patients following both oral and intravenous dosing regimens.  		302285	0	302285	616622
Conivaptan	VAPRISOL	13	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  12.3 Pharmacokinetics    The pharmacokinetics of conivaptan have been characterized in healthy subjects, special populations and patients following both oral and intravenous dosing regimens.  		302285	0	302285	616622
Conivaptan	VAPRISOL	31	32	false	none	However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	31	32	false	none	However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	30	32	false	none	Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
Conivaptan	VAPRISOL	30	32	false	none	Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
Conivaptan	p450	23	24	true	positive	Distribution    Conivaptan is extensively bound to human plasma proteins, being 99% bound over the concentration range of approximately 10 to 1000 ng/mL.  Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
Conivaptan	p450	23	24	true	positive	Distribution    Conivaptan is extensively bound to human plasma proteins, being 99% bound over the concentration range of approximately 10 to 1000 ng/mL.  Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
Conivaptan	p450	24	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
Conivaptan	p450	24	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
Conivaptan	p450	26	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  Four metabolites have been identified.  The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  		302285	none	302285	none
Conivaptan	p450	26	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  Four metabolites have been identified.  The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  		302285	none	302285	none
vasopressin	conivaptan	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		none	302285	none	302285
vasopressin	conivaptan	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		none	302285	none	302285
vasopressin	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		none	none	none	none
conivaptan	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	302285	none
conivaptan	arginine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.  		302285	none	302285	none
conivaptan	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
conivaptan	moxifloxacin	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
conivaptan	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
conivaptan	moxifloxacin	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	139462	302285	139462
conivaptan	moxifloxacin	12	10	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	139462	302285	139462
conivaptan	moxifloxacin	12	10	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	139462	302285	139462
conivaptan	VAPRISOL	34	35	false	none	However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
conivaptan	VAPRISOL	34	35	false	none	However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
conivaptan	VAPRISOL	34	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  		302285	0	302285	616622
conivaptan	VAPRISOL	34	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  		302285	0	302285	616622
conivaptan	VAPRISOL	35	35	false	none	In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
conivaptan	VAPRISOL	35	35	false	none	In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
conivaptan	VAPRISOL	32	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
conivaptan	VAPRISOL	32	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
conivaptan	VAPRISOL	33	35	false	none	Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
conivaptan	VAPRISOL	33	35	false	none	Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.  In study subjects without renal impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].  		302285	0	302285	616622
conivaptan	VAPRISOL	33	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  		302285	0	302285	616622
conivaptan	VAPRISOL	33	32	false	none	In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  Renal Impairment    The effect of renal impairment on the elimination of conivaptan after intravenous administration has not been evaluated.  		302285	0	302285	616622
conivaptan	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
conivaptan	VAPRISOL	6	8	false	none	12.2 Pharmacodynamics    The pharmacodynamic effects of conivaptan hydrochloride include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.  Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
conivaptan	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
conivaptan	VAPRISOL	7	8	false	none	Studies in animal models of hyponatremia showed that conivaptan hydrochloride prevented the occurrence of hyponatremia-related physical signs in rats with the syndrome of inappropriate antidiuretic hormone secretion.  Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		302285	0	302285	616622
conivaptan	VAPRISOL	12	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	0	302285	616622
conivaptan	VAPRISOL	12	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  		302285	0	302285	616622
conivaptan	VAPRISOL	13	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  12.3 Pharmacokinetics    The pharmacokinetics of conivaptan have been characterized in healthy subjects, special populations and patients following both oral and intravenous dosing regimens.  		302285	0	302285	616622
conivaptan	VAPRISOL	13	11	false	none	The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  The results suggest that conivaptan has no clinically significant effect on cardiac repolarization.  12.3 Pharmacokinetics    The pharmacokinetics of conivaptan have been characterized in healthy subjects, special populations and patients following both oral and intravenous dosing regimens.  		302285	0	302285	616622
conivaptan	VAPRISOL	31	32	false	none	However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
conivaptan	VAPRISOL	31	32	false	none	However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
conivaptan	VAPRISOL	30	32	false	none	Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
conivaptan	VAPRISOL	30	32	false	none	Special Populations    Hepatic Impairment    The effect of hepatic impairment (including ascites, cirrhosis, or portal hypertension) on the elimination of conivaptan after intravenous administration has not been systematically evaluated.  However, increased systemic exposure after oral conivaptan (up to a mean 2.8-fold increase) have been seen in patients with stable cirrhosis and moderate hepatic impairment.  In study subjects without hepatic function impairment, VAPRISOL resulted in higher conivaptan exposure than did oral conivaptan [see Warnings and Precautions (5.5) and Use in Specific Populations (8.6)].  		302285	0	302285	616622
conivaptan	p450	23	24	true	positive	Distribution    Conivaptan is extensively bound to human plasma proteins, being 99% bound over the concentration range of approximately 10 to 1000 ng/mL.  Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
conivaptan	p450	23	24	true	positive	Distribution    Conivaptan is extensively bound to human plasma proteins, being 99% bound over the concentration range of approximately 10 to 1000 ng/mL.  Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
conivaptan	p450	24	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
conivaptan	p450	24	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  		302285	none	302285	none
conivaptan	p450	26	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  Four metabolites have been identified.  The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  		302285	none	302285	none
conivaptan	p450	26	24	false	none	Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.  Four metabolites have been identified.  The pharmacological activity of the metabolites at V1A and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.  		302285	none	302285	none
moxifloxacin	VAPRISOL	8	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	0	139462	616622
moxifloxacin	VAPRISOL	8	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  		139462	0	139462	616622
moxifloxacin	VAPRISOL	10	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  Digital ECGs were obtained at baseline and on Days 1 and 4.  Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  		139462	0	139462	616622
moxifloxacin	VAPRISOL	10	8	false	none	Electrophysiology    The effect of VAPRISOL 40 mg IV and 80 mg IV on the QT interval was evaluated after the first dose (Day 1) and at the last day during treatment (Day 4) in a randomized, single-blind, parallel group, placebo- and positive-controlled (moxifloxacin 400 mg IV) study in healthy male and female volunteers aged 18 to 45 years.  Digital ECGs were obtained at baseline and on Days 1 and 4.  Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  		139462	0	139462	616622
moxifloxacin	VAPRISOL	10	11	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  		139462	0	139462	616622
moxifloxacin	VAPRISOL	10	11	false	none	Moxifloxacin elicited placebo-corrected changes from baseline in individualized QT correction (QTcI) of +7 to +10 msec on Days 1 and 4, respectively, indicating that the study had assay sensitivity.  The placebo-corrected changes from baseline in QTcI in the VAPRISOL 40 mg and 80 mg dose groups on Day 1 were -3.5 msec and -2.9 msec, respectively, and -2.1 msec for both dose groups on Day 4.  		139462	0	139462	616622
